Medullary Thyroid Cancer
Oncology·MeSH: Carcinoma, Medullary
Prevalence
30.9 / 100K
Incidence
3.9 / 100K/yr
2 drugs in development·2 companies·5 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| COMETRIQ | EXELIXIS, INC. (EXEL) |
Phase 3(1)
| Drug | Company |
|---|---|
| cabozantinib | LOXO ONCOLOGY, INC. (LOXO) |
Compare drugs
Frequently asked questions
How many drugs are in development for Medullary Thyroid Cancer?
BioSniper tracks 2 drugs in development for Medullary Thyroid Cancer across 2 companies.
How many clinical trials target Medullary Thyroid Cancer?
There are 5 clinical trials targeting Medullary Thyroid Cancer tracked by BioSniper.
What is the prevalence of Medullary Thyroid Cancer?
The estimated prevalence of Medullary Thyroid Cancer is approximately 30.9 per 100,000 population.
Deep-dive into Medullary Thyroid Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis